Avita Medical, Inc. · NASDAQ:RCEL

Avita Medical — Investor Presentation (February 2014)

24 slides from Avita Medical's investor presentation, Feb 11, 2014

  1. Slide 1: Investor Presentation

    Galatéa de las esferas Salvador Dalí, 1952 Investor Presentation 11 February 2014

  2. Slide 2: Forward-looking statements disclaimer

    This presentation may include forward‐looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. These forward looking statements speak onl

  3. Slide 3: Lead product ReCell Spray-On Skin overview

     Lead product ReCell® Spray‐On Skin ® point‐of‐ care regeneration treatment for wide range of chronic and acute wounds, pigmentation and other dermal defects  Australian Exchange (ASX:AVH); US Exchange / ADR (OTCQX: AVMXY) − Market capitalisation: $42M* − Cash on hand (as at 31 December 2013): $6.

  4. Slide 4: Unique. Innovative. Targeted.

     Avita Medical Limited is a publicly listed, global Unique. medical technology company that develops and distributes a highly innovative product in Innovative.  regenerative medicine. Avita’s unique regenerative product, ReCell, is Targeted. being tested and proven by clinics in Asia/Pacific, Euro

  5. Slide 5: Half-year highlights

     ReCell revenues increased by 35% compared to quarter ending 31 December 2012  Total revenues for the half‐year at A$1.8M  Cash balance A$6.8M, with no debt  Positive progress in clinical, sales and reimbursement in China  Sales & Marketing resources restructure supports increased engagement an

  6. Slide 6: Avita Medical ReCell Breath-A-Tech distribution

    Avita Medical ReCell Breath‐A‐Tech Clinical Distribution Distribution • US • UK • Australia • UK • Australia • Germany • Germany • France • France • Netherlands • Italy • Turkey • China |6

  7. Slide 7: Direct, distributor and joint venture structure

    Avita Medical Europe Cambridge, UK Avita Medical Americas Avita Medical Italia Los Angeles Milan, Italy Direct Avita Medical Asia Distributor Pacific Australia Joint Venture Regulatory trials in progress |7

  8. Slide 8: Estimated annual procedures by condition

    Condition Estimated annual procedures Chronic wounds 22,644,000 (lower limb ulcers) Vitiligo 19,622,000 Aesthetics/Plastics 1,998,000 Burns 5,021,000 TOTAL 49.3 million |8

  9. Slide 9: ReCell revenues up 35%

     ReCell revenues up 35% Q2FY12 v Q2FY13 Key Market Revenue compared to quarter ending 31 December 2012  52% United Kingdom  ReCell revenues increased 11%  29% Australia for the financial year to date  Head of Sales & Marketing appointed to drive customer YTD FY12 v YTD FY13 Unit Sales engagemen

  10. Slide 10: Clear business path: burns, aesthetics, chronic wounds

    Avita Medical has identified a clear business path: 3. Continue to develop 1. Expand burns 2. Progress aesthetics chronic wounds Build sales of ReCell in markets where treatment Progress aesthetic Advance clinical trials to for burns is approved. treatment to derive continue the revenue from a large

  11. Slide 11: Development path from pre-clinical to sales

    Pre‐clinical Clinical Sales and distribution Opportunity Prefeasibility Clinical trial Clinical trial Product Engage new identified initiated engaged managed approved customers Unique product Initial stage Criteria set and Trial process If criteria met, Product or indication studies trial intensely

  12. Slide 12: Indications by stage and region

    Indications Preclinical Clinical Market USA Acute burns/trauma EMEA ROW USA Aesthetics EMEA Scars and vitiligo ROW USA Chronic Wounds EMEA ROW USA Research & Development EMEA ROW | 12

  13. Slide 13: What are reimbursements?

    What are reimbursements?  Coverage and reimbursement by a healthcare payer, whether commercial, private or government (e.g., UK’s NHS or Australia’s Medicare) required to allow provider to be compensated by the healthcare payer. What are the challenges faced in obtaining reimbursements?  In the pr

  14. Slide 14: Reimbursement progress by country

    United Kingdom  NICE (National Institute for Health and Care Excellence)application submitted  Under review by Medical Technologies Advisory Committee (MTAC)  Draft Scope available for comment Germany  Supporting application submitted by eight hospitals, multiple authorities involved including:

  15. Slide 15: Avita's Regenerative Technology

    Avita’s Regenerative Technology  Harnesses the body’s intrinsic ability to heal itself and packages it into an easy‐to‐use bedside kit for the clinician.  Addresses needs of all stakeholders: − Patients: Provides improved outcomes and quality‐of‐life; − Surgeon/Clinician: Easy, fast and effective

  16. Slide 16: ReCell treatment steps

    Step 1  Small, thin (split‐thickness) skin sample processed  30‐minutes to prepare a cell suspension  Ready for immediate application Step 2  Cell proliferation  Modulation of wound healing environment Step 3  Epidermal closure (within week one)  Skin maturation (as early as two weeks after c

  17. Slide 17: Cost of treatment savings with ReCell

    60000 42% 45% 40% 50000 34% % Savings achieved with ReCell 32% 35% 30% Cost of Treatment (£) 40000 30% 25% 25% 30000 20% 20000 15% 10% 10000 5% 0 0% 2 5 10 15 20 Total Body Surface Area (%) % Savings COST SOC COST RC Data based on recorded expenses in treatment of 26 burns patients at Pinderfields H

  18. Slide 18: ReCell usages and publications by year

     Number of usages (excluding clinical studies)  Number of publications 1 Jan – 8 Nov 2013 ReCell Uses by Year ReCell Publications by Year 1000 35 30 800 25 600 20 400 15 10 200 5 0 0 2007 2008 2009 2010 2011 2012 2013 2007 2008 2009 2010 2011 2012 2013 | 18

  19. Slide 19: Chronic ulcer healing results

     More than 60% of ulcers healed within 60 days of treatment  Patients had suffered from these ulcers for an average of 18 months prior treatment DFU Healing at 60 days Healing at 60 days Average Ulcer Duration: 28 months Average Ulcer Duration: 18.3 months Average Rectangular Area: 8.7 sq cm 20 4

  20. Slide 20: Commercialisation focus for ReCell

    1 Focus on the commercialisation of ReCell technology with reinvigorated sales and marketing program focussing on health and economic benefits 2 Demonstrate to new customers how ReCell technology can improve their clinic’s revenue stream, aligning the product with the market. 3 Synchronise Avita Med

  21. Slide 21: Target event dates

    Event Target Date ReCell (product): Roll‐out of Ambient‐stored Enzyme in UK/Europe 1Q2014 Non‐dilutive $: R&D Tax Refund 2Q2014 Burns: US Compassionate Use Cohort IDE Submission 2Q2014 Adjunct ReCell treatment for large acute burns/trauma Burns: US Acute Burn IDE Submission Adjunct ReCell treatment

  22. Slide 22: Regenerative sector peer comparison

    Company Sector Revenue FY2013 Net Profit FY2013 Market cap* Exchange Ticker Avita Medical Regenerative A$2.81M ‐A$8.09M A$42.49M ASX AVH Clinuvel Regenerative A$2.49M ‐A$6.80M A$56.94M ASX CUV Tissue Therapies Regenerative A$95.00K ‐A$5.74M A$89.37M ASX TIS Cytori Therapeutics Regenerative US$16.06M

  23. Slide 23: Management team

    Timothy Rooney, Interim CEO: 20 years senior finance and operations management; pharmaceutical wholesale distribution and medical device industries Lorraine Glover, General Manager, Asia Pacific: 22 years experience in the commercial biotechnology and medical devices industry Andrew Quick, VP Resear

  24. Slide 24: For more information

    For more information www.avitamedical.com avita

Avita Medical — Investor Presentation (February 2014) on 6ix